

William Webster, Pharm.D., FCCP

FUNDING: GRANTS and APPROVED PROTOCOLS as 5/27/1999

1998 to present CP-98-020 Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma. BB-IND 3323 Harwood SJ - Principal Investigator, **Webster W, Co-Investigator** Coulter Pharmaceutical, Palo Alto, Ca \$16,000 to date

1998 to present A prospective Study of the AcuTect Imaging Characteristics of Patients with Acute Deep Vein Thrombosis and Patients with Post Phlebitic Syndrome. (Phase IV) Harwood, SJ, and **Webster, W.B. Principal Investigators.** Diatide, Inc., Londonberry NH. \$ 79,000.

1997 to present Effects of Enoxaparin on TFPI and Anti-Xa Release in Prophylaxis of VTED in Hip of Knee Arthroplasty Surgery. Hakki S, Camblin J, **Webster WB**, Hill K, Fareed T. Bay Pines VAMC, Extramural funding pending.

1997 to present A Multicenter Open-label Study Evaluating the Safety of Technetium (Tc-99m) P280 in Patients at Risk for Venous Thrombosis. (Phase III) Harwood SJ - Principal Investigator, **Webster W**, Camblin J, Hakki S, Webster T, Carroll R. Diatide, Inc., Londonberry NH.

1997 to present A Multicenter, Double-Blind, Four-Arm, Parallel-Group, Comparative Study to Evaluate the Safety and Efficacy of Sn-117m DTPA and Metastron for Palliation of Bone Pain from Osseous Metastases in Prostate Cancer Patients. (Phase III) Harwood SJ - Principal Investigator, **Webster W**, Sochet A, Hakki S, Tantranond P, Hudson P, Morrissey M, Gibbons, L. Diatide, Inc., Londonberry NH.

1997 to present A Multi-Center Study Evaluating the Safety and Efficacy of Technetium (Tc99m) P829 for the Detection and Localization of Cancer in the Lung.(Phase III) Harwood SJ - Principal Investigator, **Webster W**, Carroll R, Parikh SL, Bonilla-Santiago J, Tannenbaum M, Riveron E, Morrissey M. Diatide, Inc., Londonberry NH.

1997 to present Utility of LymphoScan Imaging in the Detection of Residual Tumor after Chemo and/or Radiotherapy in Patients with Non-Hodgkin's Lymphoma (Protocol IM-D-LL2-05). (Phase III) **Webster, W.B.** and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ.

1997 to present The Utility of LymphoScan Imaging in the Localization and Staging of Patients with Non-Hodgkin's Lymphoma (Protocol IM-D-LL2-05).(Phase III) **Webster, W.B.** and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ.

1997 to present Pilot Study Evaluating the Safety and Efficacy of Technetium Tc99m P280 In the Detection of Carotid Artery Thrombi. (Phase II/III) **Webster, W.B.** and Harwood, SJ Co-Principal Investigators. Diatide, Inc., Londonberry NH.

1997 to present Protocol Number: 829-34, A Multi-Center Study Evaluating the Safety and Efficacy of Technetium Tc99m P829 for the Detection and Localization of Non-Small Cell Lung Cancer. (Phase III) **Webster, W.B.** and Harwood, SJ Co-Principal Investigators. Diatide, Inc., Londonberry NH.

1996 to 1997 Protocol Number: 280-11, A Multi-Center, Open Label Study evaluating the Pharmacokinetics and Radiation Dosimetry of Technetium Tc99m P280 in Patients at Risk for Venous Thrombosis.(Phase III) Harwood, SJ, and **Webster, W.B. Principal Investigators.** Diatide, Inc., Londonberry NH. \$ 65,000.

1994 to present Protocol Number IM-D-MN3-15, Comparative Pharmacokinetics, Dosimetry and In-Vivo Stability of Two Formulations of 99mTc-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoScan™) in Patients Undergoing Arthroscopic Procedures. (Phase II/III - Bioequivalence of commercial scale-up) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 60,000 to date.

1994 to present Protocol Number 1033-PK Pharmacokinetics of Tc-99m-Labeled Anti-CEA Antibody IMMU-4 Lot (Phase II/III)Commercial scale up) #304121 in Patients with Known Colorectal Carcinoma. **Webster, WB, Principal Investigator.** Immunomedics Corp., Newark, NJ. \$ 10,000 to date.

1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) in the Detection of Infected Prosthetic Joints.(Phase III) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 25,000 to date.

1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Long Bone Osteomyelitis. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 25,000 to date.

1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Osteomyelitis in Patients with Diabetic Foot Ulcers.(Phase III) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 25,000 to date.

1993 to 1994 Pharmacokinetics, Dosimetry, and Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 35,000.

1993 to 1994 Pharmacokinetics, Dosimetry and Imaging of Tc-99m-labelled Anti-CEA Antibody IMMU-4 Lot (Commercial Scale Up) #304121 in Patients with Known Colorectal Carcinoma. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators.** Immunomedics Corp., Newark, NJ. \$ 35,000.

1992 to 1993 Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators**. Immunomedics Corp., Newark, NJ. \$ 75,000.

1992 Evaluation of Safety and Efficacy in Detection of Non-Hodgkin's B-Cell Lymphoma by Diagnostic Imaging of FAB' Fragment of the Anti-Lymphoma (B-Cell) Antibody IMMU-LL-2 Labeled with Tc-99m. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators**. Immunomedics Corp., Newark, NJ, \$ 25,000.

1992 Detection of Breast Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody IMMU-4 Labeled with Tc-99m. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators**. Immunomedics Corp., Newark, NJ.

1992 Detection of Hepatocellular Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-AFP Antibody IMMU-31 Labeled with Tc-99m. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators**. Immunomedics Corp., Newark, NJ.

1992 Radioimmunodetection of Residual Recurrent or Metastatic Trophoblastic and Germinal Cell Tumors using ^{99m}Tc-Anti-hCG or Anti-AFP Antibody fab' Fragment. (Phase III) Harwood, SJ and **Webster, WB, Principal Investigators**. Immunomedics Corp., Newark, NJ.

1992 to 1993 Radioimmunoscintigraphy of Recurrent of Metastatic Colorectal Cancer with ⁹⁹Tc-88BV59H21-2V67-66, A Totally Human Antibody. Phase III Multi-center Study. (Phase III) Carroll RG, Principal Investigator, **Webster WB, Co-Investigator**. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD. \$60,000.00

1992 to 1993 Preoperative Immunoscintigraphy and Intraoperative Oncoprobe Assisted Detection of Colorectal Carcinoma after Intravenous Administration of ⁹⁹Tc-88BV59H21-2. (Phase III) Carroll RG, Principal Investigator, **Webster WB, Co-Investigator**. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD.

1991 to 1994 Post-Doctoral Fellowship (2 years) - Biotechnology: Antibody Immunoconjugates and Immunotherapeutics. **Webster WB, Principal Preceptor**, Glaxo Pharmaceutical, Research Triangle, N.C., \$ 81,000

1990 to 1993 Safety and Preliminary Efficacy of Intravenous Administration of ¹¹¹In-CYT-356 in the imaging of Prostate Cancer: Pre-surgical Staging, Dosimetry. (Phase III) Harwood SJ and **Webster WB, Principal Investigators**. Cytogen Corporation, Princeton, NJ, \$ 35,000 (to date)

1990 to 1993 Phase I/II Clinical Study: Detection of Colorectal Carcinoma Using IVP ZCE025, an ¹¹¹In-Labeled Anti-CEA MoAb (Dose Ranging Protocol). (Phase III) Carroll RG, Principal Investigator, **Webster WB, Co-Investigator**. Hybritech, La Jolla, Ca, \$ 30,000 (to date)

1989 to 1993 Repeat Intravenous Infusions of ^{111}In -CYT-103 in the Imaging and Detection of Recurrent Colorectal Carcinoma. (Phase III) Harwood SJ and **Webster WB, Principal Investigators**. Cytogen Corporation, Princeton, NJ, \$ 200,000 (to date)

1989 to 1990 ^{111}In -CYT-103 in the Imaging of Occult Colorectal Carcinoma: Dosimetry. (Phase III) Harwood and **Webster WB, Principal Investigators**. Cytogen Corporation, Princeton, NJ 1989, \$ 34,300

1988 to 1989 Phase III Study of CYT-103 ^{111}In in the Imaging of Colorectal Carcinoma: Pre-surgical Staging. Harwood SJ and **Webster WB, Principal Investigators**. Cytogen Corporation, Princeton, NJ, \$ 100,000

1988 to 1989 Phase III Study of CYT-103 ^{111}In in the Imaging of Occult Colorectal Carcinoma. (Phase III) Harwood SJ and **Webster WB, Principal Investigators**. Cytogen Corporation, Princeton, NJ, \$ 54,648

1988 Impact of a Pharmacy Based Phlebotomy service Integrated Into Aminoglycoside Clinical Pharmacokinetics Team. Lewis MJ, Principal Investigator, **Webster WB**, Co-Investigator. Bristol Laboratories, \$ 10,000

1988 Phase I/II Study of ^{111}In -CYT-103 in the Imaging of Colorectal Carcinoma. Harwood SJ and **Webster WB, Co-Principal Investigators**. Cytogen Corporation, Princeton, NJ, \$ 60,000

1987 Specificity of ZCE 025 (Fab')₂ Localization In Human Colorectal Cancer, VA Merit Review Board, Robert G. Carroll, Principal Investigator and **W. B. Webster, Co-Investigator**, \$ 60,000